nation24m
Breast cancer: Why it’s difficult to treat and how precision medicine could help
Breast cancer is challenging to treat because there are so many subtypes with unique genetic and molecular characteristics.
Daily1h
Novartis' Ribociclib named as Category 1 Preferred Adjuvant Treatment for Breast Cancer in NCCN Guidelines
Basel: This month, the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines) for breast cancer were updated to ...
GEN8h
StockWatch: Sangamo Shares Surge on Shorter Pathway for Fabry Candidate
Shares of Sangamo Therapeutics surged 69% after the genetic medicines developer announced regulatory progress in its quest to ...
Vigorous workout reduces hunger, especially in women
Vigorous exercise can help with weight loss by lowering levels of the 'hunger hormone' ghrelin, particularly in women, a ...
Pharmabiz22h
Novartis ribociclib recognized as Category 1 preferred breast cancer adjuvant treatment by NCCN Guidelines
Novartis ribociclib recognized as Category 1 preferred breast cancer adjuvant treatment by NCCN Guidelines: Basel Saturday, October 26, 2024, 14:00 Hrs [IST] This month, the NCCN ...
Medindia22h
Medicaid Expansion Boosts Cancer Care in Aggressive Breast Cancer
Medicaid expansion linked to better cancer care and survival rates for patients with aggressive breast cancer.